Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

Published Date: 23 Jul 2026

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

After all, Pulled Myeloma Drug May Help Treat the Illness.

2.

RML to develop bone marrow transplantation at Lady Hardinge Medical College in Safdarjung

3.

Stem Cell Transplant Associated With Better PFS in NKTCL

4.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

5.

A Chemo-Free Option for Some Advanced Endometrial Cancers?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot